Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
The University of Texas Health Science Center, Houston
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04387201CT.gov GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Glucose Intolerance
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vibisone (this asset) | The University of Texas Health Science Center, Houston | Approved | BB · 69 |
| Dulaglutide | University of Pennsylvania | P4 | BBB |
| Dexmedetomidine | Pontificia Universidad Catolica de Chile | P4 | BB |
| Nepenthe | Washington University School of Medicine | P4 | BB |
| Fentanyl | Pontificia Universidad Catolica de Chile | P4 | BB |
| Candesartan | Fundación Cardiovascular de Colombia | P4 | BB |
| Physiologic Sodium Chloride Solution | Pontificia Universidad Catolica de Chile | P4 | BB |
| Tadalafil | Thomas J. Wang, MD | P3 | B |
| Umbellatine | Hospital Civil de Guadalajara | P3 | B |
+7 more in the Glucose Intolerance cohort
Other indications for Vibisone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myocardial Infarction | — | P3 | BB · 66 |
| Obesity Disorder | — | P4 | BB · 65 |
| Cerebral Infarction | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vibisone in Glucose Intolerance. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vibisone-glucose-intolerance
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →